A third-party consumer research study looking at CBD’s effects on humans, meant to help gather liver safety data that the U.S. Food and Drug Administration needs to move forward with regulation, is set to begin in July.

The protocol for the study, sponsored and led by ValidCare, a Colorado-based firm that conducts clinical and market intelligence research for the hemp and healthcare industries, was developed with significant feedback from the FDA’s working group focused on CBD.

ValidCare has garnered support from seven CBD brands that are cooperating to help fund the study and recruit consumers to participate, including: